Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple Myeloma

Circulating tumor DNA faithfully recapitulates somatic mutations detected in bone marrow aspirates from patients with newly diagnosed or relapsed or recurrent myeloma. Extending these methods to enable detection of minimal residual disease will require increased sensitivity and breadth of genomic assays to maximize information content from small quantities of cell-free DNA; as well as definition of a clinically meaningful ctDNA concentration in comparison with conventional bone marrow cell-count thresholds.

Source: Seminars in Hematology - March 7, 2018 Category: Hematology Authors: Trevor J. Pugh Source Type: research